Does frozen embryo transfer improve pregnancy outcomes in patients with ovarian endometriosis? A retrospective cohort study
article
OA: closed
CC0
AI-generated summary
Frozen embryo transfer did not improve pregnancy outcomes compared to fresh embryo transfer in women with ovarian endometriosis undergoing their first IVF cycle.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
RESEARCH QUESTION: Does frozen embryo transfer improve pregnancy outcomes compared with fresh embryo transfer in women with ovarian endometriosis (OEM) undergoing their first IVF/intracytoplasmic sperm injection cycle?
DESIGN: A retrospective cohort study analysed 550 women aged 20-40 years with ultrasound-confirmed OEM who underwent their first assisted reproduction cycle between January 2020 and December 2023. Participants underwent either fresh embryo transfer (n = 170) or frozen embryo transfer (n = 380). Baseline characteristics including ovarian reserve markers, stimulation protocols, and embryo features were compared. Clinical outcomes assessed were clinical pregnancy, live birth, implantation, pregnancy loss, preterm birth, and neonatal complications. Multivariate regression models adjusted for potential confounders. Subgroup analyses considered progesterone concentration, oocyte yield, status of adenomyosis, prior surgery or medical therapy for OEM, endometrial preparation protocols, and stages of transferred embryos.
RESULTS: Women in the frozen embryo transfer group had a shorter duration of infertility and higher levels of ovarian reserve markers. Unadjusted analysis showed higher implantation, clinical pregnancy and live birth rates in the frozen embryo transfer group; however, after adjustment, no significant differences were observed in implantation rate [adjusted relative risk (RR) 0.89, 95% CI 0.67-1.19], clinical pregnancy rate (adjusted RR 0.90, 95% CI 0.68-1.19), live birth rate (adjusted RR 0.94, 95% CI 0.67-1.32), and other pregnancy and neonatal outcomes. Subgroup analyses confirmed these findings.
CONCLUSIONS: Frozen embryo transfer does not confer a benefit over fresh embryo transfer for improving the live birth rate or reducing pregnancy complications in women with OEM. Fresh embryo transfer remains a viable and potentially more time- and cost-efficient option in this patient population.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (36)
- A prospective cohort study of endometriosis and subsequent risk of infertility via openalex
- Endometriomas: their ultrasound characteristics via openalex
- Endometriosis and infertility: pathophysiology and management via openalex
- Ovarian stimulation and endometriosis progression or recurrence: a systematic review via openalex
- Pathophysiology, diagnosis, and management of endometriosis via openalex
- Prevalence of deep and ovarian endometriosis in early pregnancy: ultrasound diagnostic study via openalex
- Recurrence after surgery for endometrioma: a systematic review and meta-analyses via openalex
- The effect of endometriosis on live birth rate and other reproductive outcomes in ART cycles: a cohort study via openalex
- The freeze-all strategy after IVF: which indications? via openalex
- The "freeze-all" strategy seems to improve the chances of birth in adenomyosis-affected women via openalex
- The impact of endometrioma on IVF/ICSI outcomes: a systematic review and meta-analysis via openalex
- doi:10.1056/nejmoa1705334 via openalex
- doi:10.1210/endrev/bnac003 via openalex
- doi:10.3389/fendo.2025.1507252 via openalex
- doi:10.3310/aefu1104 via openalex
- doi:10.1016/j.rbmo.2024.104075 via openalex
- doi:10.5534/wjmh.220286 via openalex
- doi:10.1136/bmj-2024-081474 via openalex
- doi:10.1097/cm9.0000000000002609 via openalex
- doi:10.1093/hropen/hoac009 via openalex
- doi:10.1056/nejmra1810764 via openalex
- doi:10.1093/humupd/dmy033 via openalex
- doi:10.1093/humrep/dex334 via openalex
- doi:10.3390/jcm12144828 via openalex
- doi:10.1016/j.ecoenv.2020.110965 via openalex
- doi:10.1016/j.intimp.2024.112291 via openalex
- doi:10.1007/s00404-020-05796-9 via openalex
- doi:10.1038/s41467-024-52008-y via openalex
- doi:10.1016/j.fertnstert.2019.12.005 via openalex
- doi:10.1016/j.envint.2021.106544 via openalex
- doi:10.1093/humrep/deae008 via openalex
- doi:10.1016/j.fertnstert.2022.07.006 via openalex
- doi:10.1016/j.fertnstert.2020.08.813 via openalex
- doi:10.3390/medicina60081373 via openalex
- doi:10.1093/humupd/dmx031 via openalex
- doi:10.1056/nejmoa1513873 via openalex
Source provenance
- europepmc
- last seen: 2026-08-26T06:08:41.316361+00:00
- openalex
- last seen: 2026-05-11T07:05:40.409240+00:00
- pubmed
- last seen: 2026-08-26T06:04:09.326834+00:00
- unpaywall
- last seen: 2026-08-26T06:23:03.089193+00:00
License: CC0
· commercial use OK